Home › Trials › NCT05594706
Clinical trial Recruiting at 1 site Observational Ages 2 to 18

Measuring a new biomarker in children with type 1 diabetes

Official title: Anhydroglucitol as a Measure of the Functional Beta-cell Mass in Children With Type 1 Diabetes - Pilot Study

Run by University Hospital, Geneva · NCT05594706 · Data updated 2026-11-12

This study is testing a new blood marker in children with type 1 diabetes to see if it can help measure how well their insulin-producing cells are working.

More Diabetes Mellitus, Type 1 trials

Quick facts

Study typeObservational
Ages2 Years to 18 Years
SexAll
Enrollment60 (estimated)
SponsorUniversity Hospital, Geneva
Academic / other
Locations1 site (Geneva, Canton of Geneva)
StatusRecruiting
StartedJanuary 27, 2023
Main results expectedDecember 31, 2026
Study endsDecember 31, 2026
Registry record updatedMay 18, 2026
Trial IDNCT05594706 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Ideal candidates are children with type 1 diabetes who are positive for specific autoantibodies and are using continuous subcutaneous insulin infusion.

Probably not a fit

Patients treated with multiple daily injections or those unwilling to use continuous glucose monitoring systems may not benefit from this study.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study aims to measure blood levels of 1,5-anhydroglucitol in children diagnosed with type 1 diabetes and correlate these levels with indicators of functional beta-cell mass. The study will include both newly diagnosed and long-standing cases of diabetes, comparing results with healthy volunteers. Conducted at the University Hospital of Geneva, the research seeks to validate 1,5-anhydroglucitol as a potential biomarker for assessing beta-cell function in pediatric patients with type 1 diabetes.

Why it matters

Potential benefit: If successful, this study could provide a new biomarker for monitoring beta-cell function in children with type 1 diabetes, potentially improving management and treatment strategies.

How similar studies have gone: Previous studies have shown correlations between 1,5-anhydroglucitol levels and diabetes progression, indicating potential for success in this novel approach.

Who can join: the full rules

Show full inclusion / exclusion criteria 
Inclusion Criteria:

* Type 1 diabetes with positive autoantibodies against islets, insulin, islet antigen 2 (IA2), glutamic acid decarboxylase (GAD) 65 or zinc transporter (ZnT)8.
* Treatment with continuous subcutaneous insulin infusion (CSII) with or without automated insulin delivery (AID).
* Monitoring with a continuous glucose measurement system (CGMS) or flash glucose monitor (FGM).
* Patient willing to keep the same type of CGMS or FGM during the year of observation
* Ability to give informed consent as documented by signature

Exclusion Criteria:

* Patients treated with multiple daily injections (MDI) or not willing to wear a CGMS of FGM
* Patients changing the type of CGMS during the course of the study.

Where it's running

  • University Hospital of Geneva
    Geneva, Canton of Geneva, Switzerland     Recruiting

Study contacts

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
View on ClinicalTrials.gov ↗ Find more trials like this →
Browse more
Diabetes Mellitus, Type 1 68University Hospital, Geneva 70
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.